

Hee Jin Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10133066/publications.pdf>

Version: 2024-02-01

29
papers

2,481
citations

516710

16
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

4947
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	8.2	68
2	Odorant receptors in cancer. <i>BMB Reports</i> , 2022, 55, 72-80.	2.4	11
3	Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. <i>Cell Death and Disease</i> , 2021, 12, 374.	6.3	15
4	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€“High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	9.4	105
5	Durvalumab and pazopanib in patients with advanced soft tissue sarcoma: A single-center, single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11551-11551.	1.6	5
6	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	3.2	10
7	Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic analysis and review. <i>BMB Reports</i> , 2021, 54, 601-607.	2.4	7
8	Ethnic delineation of primary glioblastoma genome. <i>Cancer Medicine</i> , 2020, 9, 7352-7359.	2.8	6
9	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. <i>Genome Biology</i> , 2020, 21, 216.	8.8	73
10	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	8
11	MDSC subtypes and CD39 expression on CD8⁺ T cells predict the efficacy of antiâ€“PDâ€“1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	2.9	57
12	Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening. <i>Cancers</i> , 2020, 12, 549.	3.7	2
13	Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. <i>Nature Communications</i> , 2020, 11, 3288.	12.8	44
14	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. <i>Cancers</i> , 2020, 12, 1707.	3.7	18
15	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	8.2	20
16	Tumor edge-to-core transition promotes malignancy in primary-to-recurrent glioblastoma progression in a PLAGL1/CD109-mediated mechanism. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa163.	0.7	8
17	Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. <i>Cancer Research and Treatment</i> , 2020, 52, 41-50.	3.0	14
18	NIMG-20. MULTI-HABITAT RADIOMICS UNRAVELS DISTINCT PHENOTYPIC SUBTYPES OF GLIOBLASTOMA WITH CLINICAL AND GENOMIC SIGNIFICANCE. <i>Neuro-Oncology</i> , 2020, 22, ii151-ii151.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 222-233.	1.2	12
20	PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1120-1134.	8.5	27
21	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	8.8	16
22	Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. <i>Cancer Medicine</i> , 2018, 7, 1774-1783.	2.8	5
23	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
24	Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. <i>Cell Death and Disease</i> , 2018, 9, 792.	6.3	47
25	Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. <i>Cancer Research and Treatment</i> , 2018, 50, 1009-1022.	3.0	21
26	RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer. <i>Molecular and Cellular Biology</i> , 2017, 37, .	2.3	40
27	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	16.8	1,282
28	Spatiotemporal Evolution of the Primary Glioblastoma Genome. <i>Cancer Cell</i> , 2015, 28, 318-328.	16.8	242
29	Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e103327.	2.5	25